0A4C Stock Overview
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Altimmune, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.74 |
52 Week High | US$14.82 |
52 Week Low | US$2.35 |
Beta | 0.064 |
11 Month Change | 10.48% |
3 Month Change | 15.15% |
1 Year Change | 144.83% |
33 Year Change | -37.68% |
5 Year Change | n/a |
Change since IPO | -49.33% |
Recent News & Updates
Recent updates
Shareholder Returns
0A4C | GB Biotechs | GB Market | |
---|---|---|---|
7D | -0.7% | 0.3% | -1.1% |
1Y | 144.8% | -12.7% | 10.2% |
Return vs Industry: 0A4C exceeded the UK Biotechs industry which returned -12.7% over the past year.
Return vs Market: 0A4C exceeded the UK Market which returned 10.2% over the past year.
Price Volatility
0A4C volatility | |
---|---|
0A4C Average Weekly Movement | 10.4% |
Biotechs Industry Average Movement | 8.3% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 9.4% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4C's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A4C's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
0A4C fundamental statistics | |
---|---|
Market cap | US$479.02m |
Earnings (TTM) | -US$101.35m |
Revenue (TTM) | US$409.00k |
1,171x
P/S Ratio-4.7x
P/E RatioIs 0A4C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0A4C income statement (TTM) | |
---|---|
Revenue | US$409.00k |
Cost of Revenue | US$77.94m |
Gross Profit | -US$77.53m |
Other Expenses | US$23.82m |
Earnings | -US$101.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.43 |
Gross Margin | -18,955.99% |
Net Profit Margin | -24,778.97% |
Debt/Equity Ratio | 0% |
How did 0A4C perform over the long term?
See historical performance and comparison